Stockscreener 앱 받기
12.51
1.29%
0.15
시간 외 거래:
12.51
전일 마감가:
$12.36
열려 있는:
$12.38
하루 거래량:
606.02K
Relative Volume:
0.60
시가총액:
$657.02M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.8476
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
+0.72%
1개월 성능:
+15.39%
6개월 성능:
+76.08%
1년 성능:
+21.90%
1일 변동 폭
$12.15
$12.60
1주일 범위
$12.02
$12.60
52주 변동 폭
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.51 | 649.15M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
125.90 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
EBIT per share of Emergent BioSolutions Inc. – LSE:0IGA - TradingView — Track All Markets
Assenagon Asset Management S.A. Has $498,000 Stock Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent Biosolutions (NYSE:EBS) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
EBS (NYSE: EBS) insider files Rule 144 to sell 104,695 shares - Stock Titan
Can Emergent BioSolutions Inc. stock beat analyst upgrades2025 Risk Factors & Reliable Entry Point Alerts - Улправда
How risky is Emergent BioSolutions Inc. stock nowJuly 2025 Pullbacks & Smart Money Movement Alerts - Улправда
Is Emergent BioSolutions Inc. stock recession proofEarnings Overview Summary & Real-Time Volume Analysis Alerts - Улправда
Is Emergent BioSolutions Inc. stock a buy before product launchesQuarterly Risk Review & Technical Analysis for Trade Confirmation - Улправда
Why Emergent BioSolutions Inc. stock is a must watch ticker2025 Support & Resistance & Free Weekly Watchlist of Top Performers - Улправда
Can Emergent BioSolutions Inc. stock survive global slowdownGlobal Markets & Consistent Income Trade Recommendations - Улправда
Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership - simplywall.st
Earnings Risk: Will Emergent BioSolutions Inc. stock gain from government policiesMarket Growth Report & Risk Controlled Stock Pick Alerts - Улправда
Will Emergent BioSolutions Inc. stock profit from AI boom2025 Trade Ideas & Intraday High Probability Alerts - Улправда
Is Emergent BioSolutions Inc. (ER4) stock vulnerable to rate hikes2025 Year in Review & Safe Capital Growth Plans - DonanımHaber
What is the fair value of Emergent BioSolutions Inc. stock nowJuly 2025 Rallies & Smart Allocation Stock Reports - DonanımHaber
Is Emergent BioSolutions Inc. (ER4) stock a safe buy pre earningsWeekly Earnings Recap & AI Driven Stock Reports - DonanımHaber
How sustainable is Emergent BioSolutions Inc. stock dividend payoutStop Loss & Target Return Focused Stock Picks - Улправда
VP Lowry Surrenders 3,543 Of Emergent BioSolutions Inc [EBS] - TradingView — Track All Markets
Emergent BioSolutions (EBS) insider has shares withheld to cover taxes - Stock Titan
Emergent Biosolutions (NYSE:EBS) Earns Buy Rating from HC Wainwright - MarketBeat
EBS: HC Wainwright & Co. Reiterates Buy Rating and $15 Price Tar - GuruFocus
HC Wainwright & Co. Reiterates Emergent BioSolutions (EBS) Buy Recommendation - Nasdaq
Emergent Biosolutions (NYSE:EBS) Trading 5.9% HigherHere's Why - MarketBeat
Emergent BioSolutions Gains FDA Approval for Winnipeg Facility - The Globe and Mail
Energy Moves: Can Emergent BioSolutions Inc stock weather global recessionEarnings Growth Summary & Trade Opportunity Analysis Reports - moha.gov.vn
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - The Manila Times
Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan
Emergent BioSolutions (NYSE: EBS) gains FDA approval for raxibacumab production - Stock Titan
Emergent BioSolutions Inc Stock Analysis and ForecastEvening Star Patterns & Low Risk Capital Growth Plans - earlytimes.in
Emergent Biosolutions (NYSE:EBS) Director Sells $263,148.48 in Stock - MarketBeat
Emergent BioSolutions (EBS) director reports option exercise and stock sales - Stock Titan
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
EBS (NYSE: EBS) holder files Form 144 to sell 32,848 shares - Stock Titan
What makes Emergent BioSolutions Inc. stock appealing to growth investorsTrade Risk Report & AI Driven Stock Reports - Newser
Emergent Biosolutions Inc. $EBS Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
How cyclical is Emergent BioSolutions Inc. (ER4) stock compared to rivalsMarket Risk Report & Free Reliable Trade Execution Plans - Newser
Will Emergent BioSolutions Inc. stock split again soonBull Run & Daily Risk Controlled Trade Plans - Newser
Will Emergent BioSolutions Inc. stock reach Wall Street targets2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesTrade Entry Summary & Daily Growth Stock Investment Tips - Newser
Will Emergent BioSolutions Inc. (ER4) stock extend growth storyJuly 2025 EndofMonth & Reliable Price Action Trade Plans - Newser
Published on: 2025-12-04 04:37:47 - Newser
Is Emergent BioSolutions Inc. (ER4) stock protected from inflationJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Will Emergent BioSolutions Inc. (ER4) stock top growth indexesM&A Rumor & AI Driven Price Forecasts - Newser
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2025-12-03 01:19:03 - Newser
How Emergent BioSolutions Inc. stock compares to market leadersJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Why ETFs are accumulating Emergent BioSolutions Inc. stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Emergent BioSolutions Inc. stock is popular among millennialsInflation Watch & Weekly Top Stock Performers List - Newser
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.19%
0.08%
자본화:
|
볼륨(24시간):